PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.85%
Revenue growth under 50% of AVGO's 81.03%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
7.13%
Gross profit growth at 50-75% of AVGO's 10.08%. Martin Whitman would question if cost structure or brand is lagging.
33.59%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
33.59%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
23.11%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
25.00%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
25.00%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.76%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.55%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
0.90%
Dividend growth under 50% of AVGO's 7.78%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
68.26%
OCF growth above 1.5x AVGO's 25.10%. David Dodd would confirm a clear edge in underlying cash generation.
981.22%
FCF growth above 1.5x AVGO's 23.03%. David Dodd would verify if the firm’s strategic investments yield superior returns.
80.86%
10Y revenue/share CAGR at 50-75% of AVGO's 147.44%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
9.92%
5Y revenue/share CAGR under 50% of AVGO's 197.85%. Michael Burry would suspect a significant competitive gap or product weakness.
24.13%
3Y revenue/share CAGR under 50% of AVGO's 107.08%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
1671.53%
10Y OCF/share CAGR above 1.5x AVGO's 347.97%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
253.37%
Below 50% of AVGO's 762.99%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-23.97%
Negative 3Y OCF/share CAGR while AVGO stands at 45.06%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
1458.15%
Positive 10Y CAGR while AVGO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
80.02%
Positive 5Y CAGR while AVGO is negative. John Neff might view this as a strong mid-term relative advantage.
39.06%
Positive short-term CAGR while AVGO is negative. John Neff would see a clear advantage in near-term profit trajectory.
256.93%
Equity/share CAGR of 256.93% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
62.64%
Below 50% of AVGO's 248.22%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
48.19%
3Y equity/share CAGR at 75-90% of AVGO's 63.02%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
AR growth is negative/stable vs. AVGO's 84.95%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
0.54%
Inventory shrinking or stable vs. AVGO's 60.13%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
2.55%
Asset growth well under 50% of AVGO's 180.63%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
4.36%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-3.79%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
2.58%
R&D dropping or stable vs. AVGO's 110.53%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-4.74%
We cut SG&A while AVGO invests at 104.48%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.